In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin
- 21 May 2024
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 108, 129803
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP20ck0106414)
- Japan Society for the Promotion of Science (JP20H03627)
- Kowa Life Science Foundation
- Takeda Science Foundation
- Kobayashi Foundation for Cancer Research
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
This publication has 26 references indexed in Scilit:
- Antibody-mimetic drug conjugate with efficient internalization activity using anti-HER2 VHH and duocarmycinProtein Expression and Purification, 2023
- Antibody mimetic drug conjugate manufactured by high-yield Escherichia coli expression and non-covalent binding systemProtein Expression and Purification, 2022
- Mutations for decreasing the immunogenicity and maintaining the function of core streptavidinProtein Science, 2012
- In Vivo Chemistry for Pretargeted Tumor Imaging in Live MiceAngewandte Chemie International Edition, 2010
- Role of Biotin-Binding Affinity in Streptavidin-Based Pretargeted Radioimmunotherapy of LymphomaBioconjugate Chemistry, 2004
- Pharmacokinetics and biodistribution of genetically engineered antibodiesCurrent Opinion in Biotechnology, 2002
- A Streptavidin−Biotin Binding System That Minimizes Blocking by Endogenous BiotinBioconjugate Chemistry, 2002
- Biotin Reagents for Antibody Pretargeting. 5. Additional Studies of Biotin Conjugate Design To Provide Biotinidase StabilityBioconjugate Chemistry, 2001
- Biotinidase and its roles in biotin metabolismClinica Chimica Acta, 1996
- Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancerBioconjugate Chemistry, 1993